Kazia Therapeutics Announces Phase Ii/Iii Clinical Trial Results For Paxalisib In Glioblastoma; Company Says GBM AGILE Trial Data Shows Clinical Improvement In Prespecified Secondary Analysis
kazia therapeutics宣布Paxalisib在恶性胶质母细胞瘤的二/三期临床试验结果;公司表示GBm AGILE试验数据显示预定的次要分析有临床改善